Home Blog Page 330

FertilityCare Toronto

0

A Restorative Approach To Women’s Health

FertilityCare Toronto is a holistic- minded women’s health center with the goal of restoring couples’ fertility, as naturally as possible and in harmony with the natural cycles of a woman’s body. Located at Coxwell and Danforth in downtown Toronto, the center’s services are delivered by a diverse, interdisciplinary team of health practitioners specially trained in the medical applications of the FertilityCare System, a standardized method of fertility awareness-based natural family planning, and NaPro Technology (natural procreative technology). Practitioners affiliated with the center include medical doctors, naturopathic doctors, a registered nurse, and lay practitioners with advanced training in guiding women in the FertilityCare System and NaPro Technology. NaProTechnology is a scientifically-based and well-researched reproductive health care service that cooperates with and restores reproductive function. The FertilityCare System of charting biomarkers provides the basis for the evaluation and treatment of women’s reproductive health by the NaProTechnology approach. FertilityCare Toronto provides services to women seeking alternatives for the treatment of concerns ranging from PMS, dysmenorrhea, irregular menstrual cycles, pregnancy care and post-partum issues including post-partum depression, as well as infertility; however approximately 50% of patients visit the center with fertility-related concerns.

For readers who may not be familiar with the system, the FertilityCare System consists of tracking and classifying specific biomarkers of fertility, namely the presence and qualities of cervical mucus, in a precise, systematic manner. These biomarkers are used to give an indication of changing estrogen and progesterone levels, as well as the timing and quality of ovulation. For example, the presence of spotting or brown bleeding can indicate a progesterone deficiency. Characteristics of cervical mucus that are collected include the sensation of mucus, colour, consistency, and length of stretch. An absence or low production of cervical mucus may indicate low estrogen levels and/ or problems with ovulation. The last day that cervical mucus is present during the cycle is termed “peak day,” and is used to estimate the time of ovulation. Ovulation has been shown to occur within 36 hours of “peak” in 95% of women.

Screen Shot 2014-03-30 at 12.06.23 PM

Photos: The hardworking women of the FertilityCare Toronto centre.

In addition to systematic data collection, the FertilityCare System uses a standardized method for the classification and interpretation of this data, with a view to medical applications. The FertilityCare System was developed over the last thirty years by Dr Thomas Hilgers MD, an obstetrician based out of Creighton University in Nebraska. Dr Hilgers studied the correlation of biomarkers with objective hormone changes in a woman’s body, identifying specific disturbances and/ or deficiencies present in particular pathologies such as endometriosis and polycystic ovarian syndrome (POCS). The FertilityCare system of charting biomarkers provides the foundation for the application of NaPro Technology, an advanced medical system of fertility care that restores reproductive function. For instance, Dr Hilgers identified at least four different patterns or types of luteal phase deficiency, and established his own reference ranges for optimal estradiol and progesterone levels, which are now used by NaPro- trained physicians worldwide. Dr Hilgers established the concept of an integrated hormone profile to assess estrogen and progesterone levels over the course of the cycle, with measurement periodically or every second day of the follicular and luteal phases to assess serum estradiol and progesterone, rather than relying on a single day 22 progesterone measurement. Such a strategy allows for a more accurate assessment of hormone areas under the curve (AUC) during the entire luteal (or follicular) phase. Dr Hilgers advocated the correction of hormone disturbances relying as much as possible on bioidentical hormones such as progesterone, hCG, and estradiol.

fertility care clinic

Recently, IHP had the privilege of speaking with several members of the Toronto-based team. Dr Julia Cataudella MD, CCFP, FCP, FCMC is a medical doctor based out of the center. As a graduate of Queen’s University School of Medicine, and the University of Toronto with a specialty in Family Medicine, Dr Cataudella sees the the FertilityCare System and NaPro Technology as a tool to truly understand and solve women’s health concerns without suppressing the body’s normal function and hormone physiology. Dr Cataudella is also a member of the International Institute of Restorative Reproductive Medicine (iirrm.org), a network of health care professionals and researchers who are committed to this restorative approach. Dr Cataudella emphasizes the restorative nature of the FertilityCare System as a method of “cooperatively restoring a woman’s fertility and/ or menstrual cycle.” Application of the FertilityCare System) can restore feedback in hormone systems, thereby correcting the underlying problems affecting women’s health, without resorting to suppressive treatments such as the oral contraceptive pill (OCP). Targeted use of bioidentical hormones in sync with a woman’s cycle corrects disturbances in a way that respects the body and safeguards fertility. Dr. Cataudella emphasizes that timing of hormone administration is key in achieving outcomes, and analysis of the woman’s chart is used the help determine this. The FertilityCare System system is a proactive approach, and while it requires women to invest some time in learning the charting method, the end result is women feeling empowered, dignified, and in control of their fertility. This system can also be applied to a range of other women’s health issues as well, ranging from PMS, to irregular cycles, to endometriosis and PCOS.

Fertilitycare Toronto

In her system of practice, Dr Cataudella embodies a holistic philosophy, cognizant of treating the whole person and addressing the underlying cause of disease. She eloquently describes some of the common strategies used in the conventional approach to women’s health as suppressive and near-sighted. A common example includes prescription of the OCP as a panacea for concerns ranging from teen-PMS and acne to irregular cycles and dysmenorrhea. Such a strategy shuts down the hypothalamus- pituitary-ovary (HPO) axis, suppresses ovulation, and inhibits normal production of estrogen and progesterone, while failing to address the true cause of illness. Dr Cataudella is also critical of the long-term effects of such a strategy with respect to metabolic disturbances, cardiovascular risk including blood clots, and risk of carcinogenesis. Similarly, the conventional approach to the treatment of infertility tends to rely heavily on drugs and invasive techniques that override the woman’s own body and reproductive system, while ignoring potential long-term effects on disease risk.

In keeping with her holistic approach, Dr Cataudella complements her practice of NaPro Technology with a developed interest in natural agents. She incorporates a variety of natural strategies in her recommendations to patients, including specific dietary advice and prescription of select natural health products. She recommends a low glycemic diet higher in protein for patients with PCOS, as well as a hypoallergenic diet (gluten and/ or dairy free) as well as the GAPS diet (Gut and Psychology Syndrome diet) to address the autoimmune components of endometriosis and/ or PCOS. Supplements that may be recommended to patients include inositol, chromium, chaste tree berry, biotin, and vitamin D. For men, Dr Cataudella may recommend coenzyme Q10, alpha lipoic acid, L-carnitine, and N-acetylcysteine to enhance sperm parameters. Another more novel, innovative therapy that is being increasingly utilized by NaPro- trained physicians in the treatment of conditions such as PCOS and endometriosis is Low Dose Naltrexone (LDN), a therapy that is also commonly used by naturopathic doctors in the treatment of cancer. Administration of a low, short-acting bedtime dose of naltrexone boosts early morning (rebound) endorphin production and/ or receptivity. This increase in baseline endorphin activity has been shown to support normal immune and endocrine function in conditions such as endometriosis. High dose, daytime naltrexone (50mg) may also be used to treat conditions associated with excess opioid tone, which may inhibit ovulation. In addition, Dr Cataudella cross-refers many patients with a naturopathic doctor affiliated with the center, Dr Nora Pope, ND.

Screen Shot 2014-03-30 at 1.47.46 PM

Dr Pope has been involved with the center for over twenty years, first as a volunteer and organizational leader, and later as a charting instructor, practitioner, and naturopathic doctor. Dr Pope referred her first patient to Dr Cataudella as a result of epilepsy that followed a cyclical pattern, indicating hormonal involvement and a possible role for progesterone therapy. Since then, they have shared many patients. Dr Pope has also completed advanced training in NaPro Technology, travelling to the United States to complete her training as a Medical Consultant Auditor at Dr. Hilgers’ center. Dr Pope uses her naturopathic tools, including botanicals, nutrients, classical homeopathy, and acupuncture, to enhance the specific effects of NaPro Technology with respect to hormones and the reproductive system, as well as to enhance patients’ overall health status that may be interfering with their reproductive function.

In addition, other members of the team include Karen Hemingway CFCS, Executive Director; Margaret Smith, RN, CFCE, Education Program Director; Sylvia Heald, BEd, CFCP; Vania Branker MSc, FCP; Denise Chun, BEd, CFCP; Laura Ostoya FCP; and Natalie Mahon, BEd, FCPI. Affiliated with the center but practicing independently are two other medical doctors trained in NaPro Technology: Dr Elizabeth Tham MD, CCFP, FCFP, CFCMC and Dr Maria Wolfs MD, FRCPC, NFPMC. Dr Tham has a family practice with a focus on NaPro Technology located in Etobicoke, while Dr Wolfs is an endocrinologist at St. Michael’s Hospital in Toronto. Dr Tham has an active research interest, and has published work on the effectiveness of NaPro Technology in the Canadian Family Physician (Tham 2012).

In brief, Tham et al analyzed data from a cohort of 108 couples receiving care using NaPro Technology. Baseline characteristics of the cohort were that 18% had reported having two or more previously unexplained miscarriages. The average female age was 35.4 years, and couples had been attempting to conceive for a mean of 3.2 years. Results showed that the cumulative adjusted proportion of first live births for those completing up to 24 months of NaPro treatment was 66 per 100 couples. The cumulative adjusted proportion of first conceptions was 73 per 100 couples. Of the 51 couples who conceived, 12 couples (24%) conceived with Creighton model charting instruction alone, 35 (69%) conceived with charting plus NaPro medical treatment, and 4 (8%) conceived after additional surgical treatment. There are also NaPro researchers based out of the United States, Ireland, Africa, and Australia. NaPro researchers are connected through membership in the International Institute of Restorative Reproductive Medicine (IIRRM). For more information, please visit iirrm.org.

We congratulate FertilityCare Toronto on their work and dedication to making NaPro services available to women here in Canada.

References

FertilityCare.net. New Treatment Strategies. Low Dose Naltrexone. Patient Information. URL: http://www.fertilitycare.net/documents/ LDNInfoAug13aa.pdf Accessed 29 January 2014.

Tham E, Schliep K, Stanford J. Natural procreative technology for infertility and recurrent miscarriage: outcomes in a Canadian family practice. Can Fam Physician. 2012 May;58(5):e267-74.

Two low-dose levonorgestrel intrauterine contraceptive systems RCT

0

safety of two low-dose levonorgestrel intrauterine contraceptive systems. Nulliparous and parous women aged 18-35 years with regular menstrual cycles (21-35 days) requesting contraception were randomized to 3 years of treatment with one of two levonorgestrel intrauterine contraceptive systems: 13.5 mg total content or 19.5 mg total content. The primary outcome was the pregnancy rate, calculated as the Pearl Index. The results showed that overall, 1,432 and 1,452 women in the 13.5 mg intrauterine contraceptive system and 19.5 mg intrauterine contraceptive system groups, respectively, had a placement attempted. Over the 3-year study period, 0.33 pregnancies per 100 women-years (95% confidence interval [CI] 0.16-0.60) were observed with the 13.5 mg intrauterine contraceptive system compared with 0.31 per 100 women-years (95% CI 0.15-0.57) with the 19.5 mgintrauterine contraceptive system. At least partial expulsions occurred in 4.56% and 3.58% and discontinuation rates resulting from a reported adverse event occurred in 21.9% and 19.1%, respectively. Ten of the 20 pregnancies were ectopic. Serious adverse events included six cases of pelvic inflammatory disease and one partial uterine perforation. The authors conclude that both lower-dose levonorgestrel intrauterine contraceptive systems were effective. Obstet Gynecol, December 2013. PMID: 24240244

Baseline prostate inflammation associated with reduced risk of prostate cancer

0

This study was performed to evaluate whether baseline acute and chronic prostate inflammation among men with an initial negative biopsy for prostate cancer (PCa) increased the risk of subsequent PCa detection in a clinical trial with systematic biopsies. A retrospective analysis was performed of 6238 men aged 50 years to 75 years with prostate-specific antigen levels between 2.5 ng/mL and 10 ng/mL and a prior negative biopsy in the REduction by DUtasteride of PCa Events study who completed a 2-year biopsy. PCa, acute prostateinflammation, and chronic prostate inflammation were assessed by central review. The results showed that acute and chronic inflammation and both were detected in 46 baseline biopsies (1%), 3931 baseline biopsies (63%), and 892 baseline biopsies (14%), respectively. At the 2-year biopsy, the prevalence of PCa was 14% (N = 900 patients). On univariable and multivariable analysis, both acute and chronic inflammation were found to be significantly associated with a lower PCarisk (acute univariable: odds ratio [OR], 0.65 [P < .001] and multivariable: OR, 0.75 [P = .012] and chronic univariable: OR, 0.61 [P < .001] and multivariable: OR, 0.65 [P < .001]). At the time of 4-year biopsy, only acute inflammation was found to be associated with a lower PCa risk. Cancer, December 2013. PMID: 24323568

Effects of a formal exercise program on Parkinson’s disease

0

In this study, 31 patients were randomized to an early start group (ESG) or a delayed start group (DSG) exercise program. The ESG underwent a rigorous formal group exercise program for 1 h, three days/week, for 48 weeks. The DSG participated in this identical exercise program from weeks 24-48. Outcome measures included the Unified Parkinson’s Disease Rating Scale (UPDRS), Walking Test (get-up-and-go), and the Beck Depression Inventory. The results did not show improvement in total UPDRS scores with early exercise. At week 48, the mean change from baseline total UPDRS score was 6.33 in the ESG versus 5.13 in the DSG (p = 0.58). However, patients randomized to the ESG scored significantly better on the Beck Depression Inventory, with a mean improvement of 1.07 points relative to those in the DSG (p = 0.04). The authors conclude that long-term, group exercise programs are feasible in the Parkinson’s disease population, with excellent adherence and minimal drop out. While the outcome measures used in the study did not provide strong evidence that exercise has a neuroprotective effect on motor function, earlier participation in a group exercise program had a significant effect on symptoms of depression. Parkinsonism Relat Disord, October 2013. PMID: 24209458

Impact of gender on the heart’s metabolic responses to diabetic therapies

0

This study aimed to determine whether gender affects the myocardial metabolic response to lipid lowering in T2DM, and whether altering lipid [fatty acid (FA) or triglyceride] delivery to the heart would lower the elevated myocardial lipid metabolism associated with T2DM, and whether decreasing lipid delivery improves diastolic dysfunction in T2DM. The authors studied 78 T2DM patients (43 women) with positron emission tomography, echocardiography, and whole body tracer studies before and 3 months after randomization to metformin (MET), metformin + rosiglitazone (ROSI), or metformin + Lovaza (LOV). The results showed that in men, MET decreased FA clearance, which was linked to increased plasma FA levels, myocardial FA utilization and oxidation, and lower myocardial glucose utilization. In women, ROSI increased FA clearance, thereby decreasing plasma FA levels and myocardial FA utilization. Although LOV did not change triglyceride levels, it improved diastolic function, particularly in men. Group and gender also interacted in determining myocardial glucose uptake. Thus, in T2DM, different therapeutic regimens impact myocardial metabolism and diastolic function in a gender-specific manner. This suggests that gender should be taken into account when designing a patient’s diabetes treatment. Am J Physiol Heart Circ Physiol, December 2013. PMID: 24043256

Effects of coffee, smoking, and hormones on primary sclerosing cholangitis

0

In this study, a questionnaire was distributed to hospital-recruited patients with primary sclerosing cholangitis (PSC). The results showed that a lower proportion of patients with PSC were daily coffee drinkers than control subjects, both currently (76% vs 86%; odds ratio [OR], 0.52) and at the age of 18 years (35% vs 49%; OR, 0.58). The associations were mainly attributed to differences observed in men. Twenty percent of the patients were ever (current or former) daily smokers compared with 43% of control subjects (OR, 0.33). Ever daily smoking before PSC diagnosis was associated with older age at diagnosis (42 years vs 32 years). Ever daily smoking and being a coffee drinker at the age of 18 years were independently and negatively associated with PSC. Fewer female patients with PSC than control subjects reported ever use of hormonal contraception. Among female patients, there was a strong correlation between increasing number of children before the diagnosis of PSC and increasing age at diagnosis (r = 0.63). The authors conclude that coffee consumption and smoking might protect against development of PSC. In women, the disease might be influenced by hormonal factors. Clin Gastroenterol Hepatol, September 2013. PMID: 24076415

Effect of CPAP on blood pressure for sleep apnea

0

This open-label, randomized, multicenter clinical trial of parallel groups used blinded endpoint design, and was conducted in 24 teaching hospitals in Spain involving 194 patients with resistant hypertension and an apnea-hypopnea index (AHI) of 15 or higher. The interventions were CPAP or no therapy while maintaining usual blood pressure control medication. The primary end point was the change in 24-hour mean blood pressure after 12 weeks. The results showed that 194 patients were randomly assigned to receive CPAP or no CPAP. When the changes in blood pressure over the study period were compared between groups, the CPAP group achieved a greater decrease in 24-hour mean blood pressure (3.1 mm Hg) and 24-hour DBP (3.2 mm Hg), but not in 24-hour SBP compared with the control group. Moreover, the percentage of patients displaying a nocturnal blood pressure dipper pattern at the 12-week follow-up was greater in the CPAP group than in the control group (35.9% vs 21.6%; adjusted odds ratio [OR], 2.4). There was a significant positive correlation between hours of CPAP use and the decrease in 24-hour mean blood pressure (r = 0.29, P = .006), SBP (r = 0.25; P = .02), and DBP (r = 0.30, P = .005). JAMA, December 2013. PMID: 24327037

A survey of Phthalates and Parabens in Personal Care Products and its implications

0

In this study, nine phthalates and six parabens were determined in 170 personal care products (PCPs) (41 rinse-off and 109 leave-on), including 20 baby care products collected from Albany, New York. The results showed that phthalates were less frequently found in rinse-off PCPs but were more frequently found in perfumes (detection frequency of 100% for diethyl phthalate [DEP], 67% for dibutyl phthalate [DBP]), skin toners (90% for DEP), and nail polishes (90% for DBP). Parabens were found in 40% of rinse-off products and 60% of leave-on products. The highest concentrations of DEP, DBP, methyl- (MeP), ethyl- (EtP), propyl- (PrP), and butyl parabens (BuP) were on the order of 1000 μg per gram of the product. The calculated dermal intake of phthalates from PCPs was lower for infants and toddlers than for adult females. The calculated maximum daily exposure dose of MeP, EtP, and PrP from PCPs ranged between 58.6 and 766 μg/kg-bw/day for infants and toddlers, which was 3 times higher than that calculated for adult females. PCPs are an important source of human exposure to parabens; the contribution of PCPs to phthalate exposure is low, except for DEP. Environ Sci Technol, November 2013. PMID: 24261694

An overview of Sucralose as a synthetic organocholorine sweetener

0

organochlorine sweetener (OC) that is a common ingredient in the food supply. Sucralose interacts with chemosensors in the alimentary tract that play a role in sweet taste sensation and hormone secretion. In rats, sucralose ingestion was shown to increase the expression of the efflux transporter P-glycoprotein (P-gp) and two cytochrome P-450 (CYP) isozymes in the intestine. P-gp and CYP are key components of the presystemic detoxification system involved in first-pass drug metabolism. The effect of sucralose on first-pass drug metabolism in humans is unknown. In rats, sucralose alters the microbial composition in the gastrointestinal tract (GIT), with relatively greater reduction in beneficial bacteria. The identity and safety profile of these putative sucralose metabolites are not known at this time. Sucralose and one of its hydrolysis products were found to be mutagenic at elevated concentrations in several testing methods. Cooking with sucralose at high temperatures was reported to generate chloropropanols, a potentially toxic class of compounds. Both human and rodent studies demonstrated that sucralose may alter glucose, insulin, and glucagon-like peptide 1 (GLP-1) levels. Taken together, these findings indicate that sucralose is not biologically inert. J Toxicol Environ Health B Crit Rev. 2013. PMID: 24219506

Healthy lifestyles reduce chronic diseases and dementia

0

This cohort study followed 2235 healthy men aged 45-59 starting in 1979, in Caerphilly, UK. During the following 30 years, incident diabetes, vascular disease, cancer, and death were recorded, and cognitive state was determined. The results showed that men who followed four or five of the healthy lifestyle behaviours (non-smoking, an acceptable BMI, a high fruit and vegetable intake, regular physical activity, and low/moderate alcohol intake) had an odds ratio (OR) and confidence intervals (CI) for diabetes, corrected for age and social class, of 0.50. For vascular disease the OR was 0.50, and there was a delay in vascular disease events of up to 12 years. Cancer incidence was not significantly related to lifestyle although there was a reduction associated with non-smoking (OR: 0.65). All cause mortality was reduced in men following four or five behaviours (OR 0.40). The OR for men following four or five healthy behaviours was 0.36 for cognitive impairment, and 0.36 for dementia. The adoption of a healthy lifestyle by men was low and appears not to have changed during the subsequent 30 years. The authors conclude that a healthy lifestyle is associated with increased disease-free survival and reduced cognitive impairment. PLoS One, December 2013. DOI: 10.1371/journal.pone.0081877